Understanding the Investment Landscape in Exosome Therapeutics & Evaluating the Risk Return of Clinical Validation & Scalable Platform Opportunity
- Identifying key value drivers from an investor perspective including clinical proof-ofconcept, regulatory clarity, and manufacturability at scale
- Differentiating platforms based on strength of biological rationale, delivery efficiency, and defensibility of intellectual property
- Assessing risk-adjusted return profiles across early-stage assets, focusing on translational milestones and partnering or exit opportunities